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The family of human mas-related gene-X receptors (hMrgX) comprises 4 receptor subtypes that belong to the superfamily of G protein-coupled receptors (GPCR) (Dong et al., 2001 ). Of these four subtypes only the hMrgX1 and -2 are further characterised. hMrgX1 are exclusively expressed in dorsal root ganglia (DRG) neurons (Dong et al., 2001; Lembo et al., 2002) while hMrgX2 are additionally expressed in many other tissues (Robas et al., 2003) . The endogenous ligands of hMrgX1 originate from pro-enkephalin that also gives rise to opioids such as leu-and met-enkephalin (Lembo et al., 2002) . In addition, pro-enkephalin produces biologically active compounds named bovine adrenal medulla (BAM) peptides, that have been found to occur under physiological conditions (Dores et al., 1990; Hollt et al., 1982) . BAM22 has the ability to activate hMrgX1 and opioid receptors, because its extreme N-terminus harbours the classical enkephalin motif that is responsible for high-affinity binding to opioid receptors, whereas the C-terminal portion of BAM22 binds hMrgX1. Full agonistic activity towards hMrgX1 is preserved following removal of seven N-terminal residues, because the BAM8-22 fragment exhibits similar high potency and efficacy to activate Mrg receptors when compared to the entire BAM22 peptide (Grazzini et al., 2004; Lembo et al., 2002) . Among rodents no clear orthologs of hMrgX1 could be found (Burstein et al., 2006) . However, murine and rat MrgC receptors share ~65 % sequence homology and similarities in terms of expression pattern and binding profile with hMrgX1 (Dong et al., 2001; Grazzini et al., 2004; Han et al., 2002; Lembo et al., 2002) . Therefore rodents appear as reasonable model systems to investigate the physiological role of BAM8-22 and hMrgX1. In addition to BAM peptides, the pro-opiomelanocortin (POMC) cleavage product γ 2 -MSH has also been shown to activate Mrg receptors. For mMrgC receptors BAM8-22 and γ 2 -MSH were found to be equally potent (Han et al., 2002) while in hMrgX1 expressing cells BAM8-22 (Lembo et al., 2002) and in rMrgC expressing cells (Grazzini et al., This article has not been copyedited and formatted. The final version may differ from this version. Given the exclusive expression of hMrgX and MrgC in DRG, it has been proposed that they are involved in controlling nociception and therefore represent promising therapeutic targets for pain therapy. In agreement with this prediction, application of BAM8-22 increased painaverting behaviour in rats or mice after challenging animals with heat (Chang et al., 2009; Grazzini et al., 2004) , pointing to algetic actions of this peptide. However, since then conflictive data have been reported, because BAM8-22 has also been shown to decrease nociception in rats after challenging animals with either formalin or heat, thus also pointing to an analgetic role of BAM8-22-promoted signalling (Chen et al., 2006; Hong et al., 2004; Zeng et al., 2004) .
Considering the G protein coupling properties of Mrg receptors all studies agree that they activate phospholipases C via G q proteins (Breit et al., 2006a; Dong et al., 2001; Han et al., 2002; Lembo et al., 2002) , whereas some studies suggest the involvement of pertussis toxin sensitive G proteins in hMrgX1-induced signalling (Burstein et al., 2006; Chen and Ikeda, 2004; Gales et al., 2005) . The pain mediating vanilloid receptor-1 (Hager et al., 2008; Honan and McNaughton, 2007) , voltage-gated calcium and M-type potassium channels (Chen and Ikeda, 2004) (Menard et al., 1997; Zhang et al., 1997 ), significant mMrgC endocytosis was not detectable but could be retrieved by recombinant co-expression of either β -arrestin-1 or -2, suggesting that mMrgC but not hMrgX1 functionally interact with arrestins. Differences in agonist-promoted receptor endocytosis among distinct species were also detectable in a more physiologically relevant cellular setting since they were found in two DRG-like cell lines recombinantly expressing either receptor. Interestingly, the rat MrgC was also found to be sensitive to receptor endocytosis in the same settings, strongly indicating that regulation of human and rodent BAM8-22-sensitive Mrg receptors is fundamentally different.
This article has not been copyedited and formatted. The final version may differ from this version. PD ELISA-substrate, BSA, pluronic F-127 and poly-L-lysine were from Sigma-Aldrich (Deisenhofen, Germany) and fura-2-AM was obtained from Fluka (Deisenhofen, Germany).
BAM22 and BAM8-22 were purchased from Biotrend (Cologne, Germany). Carbachol, α -and γ 2 -MSH were from Sigma-Aldrich (Deisenhofen, Germany).
Eukaryotic expression vectors.
For endocytosis experiments, expression vectors encoding the human hMrgX1 (accession number: AF474990), the rat rMrgC (accession number: AF518245) or the murine mMrgC (accession number: AY152435) fused to the Xpress epitope (pcDNA4-hMrgX1, pcDNA4-rMrgC and pcDNA4-mMrgC) were generated as follows: PCR-fragments containing the entire coding sequences excluding the start codon of the human hMrgX1 (Fprimer: 5`-ATCGATCCAACGGTCTCAACC-3`, R-primer: 5`-CGTCTAGATCACTGCTCC-AATCTGC-3`), of the rat rMrgC (F-primer: 5`-ATCGATCCAACCATCTCATCC-3`, R-primer:
5`-CGTCTAGATCAACATCTCCTTTCTG-3´) or of the murine mMrgC (F-primer: 5`-ATC-
This article has not been copyedited and formatted. The final version may differ from this version. (Breit et al., 2006b ) and of the β -arrestin-1-YFP and β -arrestin-2-YFP plasmids (Hoffmann et al., 2008) has previously been reported. cells. However, receptor expression levels were ~3 times higher in HEK293-Ex-hMrgX1 when compared to HEK293-Ex-mMrgC cells. The BAM8-22 peptide has been shown to selectively bind and activate both hMrgX1 and mMrgC (Han et al., 2002; Lembo et al., 2002) . In agreement with these previous observations, BAM8-22 induced robust calcium transients in HEK293 cells stably expressing either receptor, while mock transfected cells were unresponsive (Fig. 1B) . In addition to BAM peptides, γ 2 -MSH has also been described to activate mMrgC (Han et al., 2002) and hMrgX1 (Lembo et al., 2002) receptors. These studies revealed that γ 2 -MSH was less potent than BAM8-22 in hMrgX1 expressing cells but equally potent in mMrgC cells. However, in our cells and settings, we obtained significant signals with 1 µM γ 2 -MSH in mMrgC but not in hMrgX1 expressing cells (Fig. 1C) . Thus, for the further analysis of the regulation of agonistpromoted Mrg receptor signalling, we used BAM-peptides for the hMrgX1 and additionally γ 2 -MSH for the mMrgC.
This article has not been copyedited and formatted. The final version may differ from this version. To get a first idea about the regulation of Mrg receptor signalling, we analysed the effects of sustained agonist exposure on Mrg receptor-induced calcium transients. Therefore, we prestimulated fura-2 labelled cells with 1 µM BAM8-22 for 30 min at 37 °C and compared their abilities to yield BAM8-22-promoted calcium transients with those of untreated control cells. As expected from a given GPCR sustained pre-stimulation of HEK293-Ex-mMrgC cells reduced the ability of BAM8-22 to promote calcium signals. In fact, the AUC of BAM8-22-induced calcium signals were reduced by 60 % in comparison to control cells ( Fig. 2A) . Pre-stimulation of the same cells had no overall detrimental effects on the ability of HEK293 cells to respond with calcium signals, since agonist stimulation of the endogenously expressed muscarinic-3 receptor (Luo et al., 2008) was unaffected (Fig. 2B) . Surprisingly, BAM8-22 pre-incubation of HEK293-Ex-hMrgX1 cells did not affect the ability of hMrgX1 to induce calcium signals at all (Fig. 2C ),
suggesting species-specific differences in the regulation of Mrg receptor calcium signalling. To evaluate a possible molecular mechanism responsible for these differences, we analysed the effects of sustained agonist exposure on cell surface receptor levels by ELISA experiments with intact cells. In line with the lack of agonist-induced desensitization, stimulation of HEK293-ExhMrgX1 cells with either 1 or even 5 µM BAM8-22 for 30 min at 37 °C did not reduce the amount of receptor fusion proteins accessible to the antibody ( Fig. 3A and B) , suggesting that hMrgX1-induced calcium signals are not regulated by agonist-promoted endocytosis. In line with this notion, the extended peptide BAM22, which has been described to be a bivalent agonist for Mrg and opioid receptors (Breit et al., 2006a; Lembo et al., 2002) , also failed to induce hMrgX1 endocytosis ( Fig. 3A and B) . In contrast, HEK293-Ex-mMrgC cells showed a profound loss of mMrgC receptor proteins at the cell surface after treatment with either BAM8-22 or γ 2 -MSH ( Fig. 3A and B) . The extent and kinetics of mMrgC endocytosis were comparable to endocytosis This article has not been copyedited and formatted. The final version may differ from this version. but not for the hMrgX1 suggesting that discrepancies between receptor expression levels, do not account for the differences in endocytosis. Since the extent of ligand-promoted Ex-mMrgC endocytosis observed for BAM8-22 or γ 2 -MSH was rather low (~20 % and ~10 %, respectively),
we compared these values with those obtained with the human MC3R or MC4R ( Supplementary   Fig. 1C ), which have recently been established as GPCR that undergo robust endocytosis in HEK293 cells (Breit et al., 2006b; Shinyama et al., 2003; Wachira et al., 2007) . (Platika et al., 1985) . As shown in figure 4A , F11 cells strongly responded to bradykinin but no calcium signals were obtained with Mrg receptor-specific agonists, indicating that F11 cells do not endogenously express Mrg receptors. Thus, we transiently over expressed hMrgX1 or mMrgC receptors in F11 cells. In addition, to obtain a more detailed picture of the regulation of Mrg receptor signalling among rodents, we included the rat MrgC (rMrgC) in our study.
Measuring agonist-induced calcium transients in F11 cells expressing hMrgX1, mMrgC or rMrgC, we observed that BAM8-22 is a full agonist for all three Mrg receptors (Fig. 4) . γ 2 -MSH appeared as a strong partial agonist (~92 %) of the mMrgC (Fig. 4C) and, similar to our results obtained in HEK293 cells (Fig. 1C) , did not activate the hMrgX1 (Fig. 4B ). In the case of the rMrgC, γ 2 -MSH and BAM8-22 were equally efficient (Fig. 4D ). To assess receptor endocytosis, we stimulated Mrg receptor expressing F11 cells with the corresponding peptides for 30 min at 37 °C. Thereby, we detected a robust reduction of Ex-mMrgC but not of Ex-hMrgX1 proteins on the cell surface (Fig. 5A, B Fig. 2A ) when compared to F11 cells (Fig. 4D) . Further, This article has not been copyedited and formatted. The final version may differ from this version. Fig. 2B and C) . Thus, we conclude that similar to its murine orthologue signalling induced by rMrgC is regulated by agonist-promoted receptor endocytosis in HEK293 cells.
Next, we sought to establish F11 cell lines that stably express either Mrg receptor protein.
Although, we were able to obtain F11 cells stably expressing Ex-hMrgX1, no cells were found expressing mMrgC or rMrgC. However, as shown in figure 6A cell surface expression of hMrgX1 was rather low in these cells. Interestingly, in spite of these low expression levels, marked calcium signals could be evoked (Fig. 6B ), which clearly exceeded those obtained in HEK293-Ex-hMrgX1 cells (Fig. 1B or 2C ). This favourable ratio of calcium signal over cell surface expression might reflect very efficient coupling and signalling of hMrgX1 in F11 cells.
Regardless of the efficient coupling and low expression level no ligand-induced endocytosis of hMrgX1 was detectable in these cells (Fig. 6A) . Thus, it appears that resistance of hMrgX1 to agonist-promoted endocytosis is not restricted to HEK293 cells, but also occurs in a DRG-like cell line.
Agonist-promoted Mrg receptor endocytosis in ND-C cells. Given the exclusive
expression pattern of all three Mrg receptors in DRG, we tested species-specific alterations of receptor endocytosis in a second DRG-like cell line. ND-C cells have been established as model system to analyse the pharmacological properties of DRG-specific proteins on the cellular level (Tang et al., 1994; Wood et al., 1990; Wu et al., 2008 ), thus we have chosen these cells to further determine species-specific differences in Mrg receptor endocytosis. Stimulation of ND-C cells transfected with the respective cDNAs coding for Ex-tagged Mrg receptors confirmed that both rodent MrgC receptors are prone to agonist-promoted endocytosis either induced by BAM8-22 or γ 2 -MSH and that hMrgX1 resist BAM8-22-promoted endocytosis (Fig. 7A-D) .
This article has not been copyedited and formatted. The final version may differ from this version. (Ferguson et al., 1996) . It has been reported that GPCR, e.g. the β 2 -adrenergic receptor (β-AR), internalize poorly in Cos cells that express low levels of endogenous arrestins (Menard et al., 1997; Zhang et al., 1997) . Therefore, the Cos cell model represents an excellent tool to analyse the dependence of GPCR endocytosis on the functional interactions with arrestins.
To obtain first data about putative interactions of Mrg receptors with arrestins, we transiently expressed the hMrgX1 and the mMrgC with or without arrestins in Cos cells and determined agonist-pomoted endocytosis in these cells. In agreement with our results obtained in all cell models tested before, hMrgX1 endocytosis was also absent in Cos cells and unaffected from overexpression of either β -arr-1 or β -arr-2 (Fig. 8) , suggesting that this receptor subtype does not functionally interact with arrestins. Conversely, in mMrgC expressing Cos cells, co-expression of β -arr-1 or β -arr-2 dramatically enhanced agonist-promoted receptor endocytosis (Fig. 8) ,
indicating that functional interactions between arrestins and mMrgC receptors are required for agonist-promoted mMrgC endocytosis and that differential endocytosis among Mrg receptors may reflect different affinities of these receptors to arrestins.
This article has not been copyedited and formatted. The final version may differ from this version. 
DISCUSSION
The present study was undertaken to study agonist-promoted endocytosis of BAM8-22-sensitive Mrg receptors from different species. Performing experiments in HEK239, Cos, F11
and ND-C cells, we conclude that the human MrgX1 is one of the few members within the superfamily of GPCR whose signalling is resistant to agonist-promoted endocytosis. Further, we observed species-specific differences in the response of Mrg receptors to sustained agonist exposure.
Our unexpected findings in the regulation of rodent MrgC and hMrgX1 raised the question about the mechanisms responsible for the differences observed. Since in each experiment the same peptide solution was used for each receptor, we exclude that artificial inactivation of the peptides accounts for absent endocytosis. Further, we exclude clonal variability as a possible explanation, since it was observed in a second, independent HEK293 cell clone (data not shown) and in F11 cells stably expressing hMrgX1. Increased receptor expression levels have been shown to negatively impact receptor endocytosis (Breit et al., 2006b ), most probably due to unfavourable expression ratios of the receptor protein and proteins required for receptor endocytosis (e.g. arrestins). Considering higher receptor levels in HEK293-Ex-hMrgX1
cells when compared to HEK293-Ex-mMrgC cells, this might be of particular interest. However, differences in MrgC and hMrgX1 endocytosis also prevailed after transient protein expression, although MrgC expression levels were similar as or even higher than those of the hMrgX1, indicating that increased hMrgX1 expression levels do not account for the observed differences.
Distinctions in endocytosis observed among Mrg receptors are also not due to distinct signalling profiles, since in HEK293 and F11 cells similar agonist-promoted calcium signalling was This article has not been copyedited and formatted. The final version may differ from this version. (Ferguson et al., 1996) . In contrast, endocytosis of cell surface proteins into caveolae (smaller vesicles containing the cholesterol-binding protein caveolin) is independent of arrestins. It has been proposed that Cos cells express low levels of endogenous arrestins (Menard et al., 1997; Zhang et al., 1997) and thus represent a useful tool to discriminate between receptor endocytosis into clathrin-coated pits and caveolae. Using Cos cells recombinantly overexpressing β -arr-1 or -2 with either the hMrgX1 or the mMrgC, we can clearly show that mMrgC but not hMrgX1 receptors undergo agonist-promoted endocytosis in an arrestin-dependent manner, suggesting that differential endocytosis among Mrg receptors is reflected by different affinities to arrestins. Importantly, arrestins not only terminate GPCR signalling but also initiate G-proteinindependent signalling on their own (Shenoy and Lefkowitz, 2005) . Thus, suspected differences in the interactions of arrestins with Mrg receptors of different species might not only affect the kinetics of Mrg receptor-induced signalling but could also have qualitative effects on Mrg receptor signalling.
However, it is not yet firmed whether our striking findings reflect the physiological conditions of this new GPCR family and further studies will be required to evaluate our findings in endogenous expression systems. On the other hand, although resistance of hMrgX1 to endocytosis is uncommon among GPCRs, it has been described for a few members of this protein This article has not been copyedited and formatted. The final version may differ from this version. family e.g. the β 3 -AR (Nantel et al., 1993) , the somatostatin-4 (Schreff et al., 2000) or the κ opioid receptor (Chu et al., 1997) . Absence of β 3 -AR desensitization, firstly found in recombinant expression systems (Nantel et al., 1993) , was confirmed in an endogenous cell system (Jockers et al., 1998) . Similar findings were reported for the κ opioid (Wang et al., 2008) and the somatostatin-4 receptor (Schreff et al., 2000) , indicating that lack of receptor endocytosis is not
per se an artefact due to heterologous protein expression.
Of note, Lembo et al., contemporaneously to Dong et al., discovered a new receptor family which is exclusively expressed in small-diameter DRG neurons, and therefore known as the "sensory neuron-specific G protein-coupled receptors" (SNSR) (Lembo et al., 2002) . Six members of the SNSR subfamily (SNSR1-6) were described with SNSR1 being identical to the hMrgX3, SNSR6 to the hMrgX4 and SNSR4 to the hMrgX1 characterised herein. Of the remaining members of the SNSR family only the SNSR3 (sometimes also termed hMrgX7) was further analysed. Interestingly, this receptor subtype shares the highest sequence homology with the hMrgX1 and is also activated by BAM8-22 (Lembo et al., 2002) . In fact, these two receptor subtypes are to more than 98 % identical on the protein level. Given the fact that endocytosis resistant and prone receptors are grouped within the same subfamily (e.g adrenergic or opioid receptors), it will be an interesting task for furture studies to analyse the response of the SNSR3 to prolonged agonist exposure.
In general, receptor activity regulating processes, such as endocytosis, tend to limit the strength of cellular signalling and thus prevent overstimulation of the system. In the case of the aforementioned β 3 -AR, it has been shown that absent receptor desensitization leads to longlasting physiological effects when compared to the β 2 -AR (Trochu et al., 1999) proposing that resistance of receptor endocytosis prolongs the physiological effects of a given GPCR. Further, This article has not been copyedited and formatted. The final version may differ from this version. receptor endocytosis has been shown to dramatically impact the pharmacodynamics of a given drug. In the case of opioids, for example, a strong correlation between tolerance or dependence and receptor endocytosis (RAVE: relative activity versus endocytosis) has been proposed (Alvarez et al., 2001 ). In detail, Kim et al., recently reported that mice transgenetically expressing a mutant of the µ opioid receptor which is in contrast to the wild-type receptor prone to morphine-induced endocytosis resist the development of morphine tolerance (Kim et al., 2008) .
These data highlight the correlation between tolerance and receptor endocytosis and indicate that knowledge about agonist-promoted receptor endocytosis provides useful information to interpret or predict the actions of a given drug in vivo.
Depending on the physiological role of the hMrgX1 (algetic as described by Grazzini or analgetic as described by Chen) sustained signalling due to its resistance to endocytosis may have different consequences in vivo. Prolonged signalling of an endocytosis-resistant receptor that maintains an analgetic tonus may be favourable in a situation of long-term noxious stimulation.
In this scenario, therapy of chronic pain with synthetic hMrgX1 agonists might benefit from long-lasting analgetic signalling, being advantageous over the established opioid-based therapy, which suffers significant loss of efficiency partly due to receptor desensitization (Ueda and Ueda, 2009 ). Considering algetic effects, prolonged hMrgX1 signalling could be the cause of chronic pain which could then be treated with specific antagonists or inverse agonists. In any case, the development of pain-controlling hMrgX1-specific drugs requires a suitable animal model for the testing and improvement of the pharmacodynamics of these substances. Assuming that speciesspecific differences in agonist-promoted Mrg endocytosis also occur in vivo, data of pain controlling drugs obtained in the rodent model have to be interpreted with great caution in regard to potentially prolonged or even altered modes of action when applied to humans.
This article has not been copyedited and formatted. The final version may differ from this version. final concentration in C) at time point 10 s. As a negative control only HBS buffer has been injected. Data have been normalised by defining the first ratio (1.14 s) measured as 100 %.
Results are expressed as the mean ± S.E. of 3 independent experiments performed in triplicates. Results are expressed as the mean ± S.E. of 3 independent experiments carried out in triplicates. 
